WMore world news on WWN →

Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'

NPR News

Researchers warn betting on clinical trials could incentivize insider trading and interfere with drug development. But Kalshi and Polymarket say they provide valuable information to patients.

Read Full Article on NPR News

Related stories